Clinical Trial: Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2

U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07076056) titled 'Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2' on July 13.

Brief Summary: A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy

Study Start Date: Oct. 27, 2022

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes

Intervention: DRUG: DW1026C1

Sitagliptin 100mg+Empagliflozin 10mg

DRUG: DW1026C2

Sitagliptin 100mg+Empagliflozin 25mg

DRUG: DW1026S

Sitagliptin 100mg

Recruitment Status: COM...